Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Medtronic
Mallinckrodt
Harvard Business School
Express Scripts

Last Updated: January 19, 2022

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DEPO-SUBQ PROVERA 104

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for Depo-subq Provera 104

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000897 ↗ A Study to Evaluate the Effects of Different Methods of Birth Control on the Drug Actions of Zidovudine (an Anti-HIV Drug) in HIV-Positive Women and to Compare Zidovudine Metabolism in Men and Women Completed National Institute of Allergy and Infectious Diseases (NIAID) N/A 1969-12-31 The purpose of this study is to look at the effects of different methods of birth control (oral and injectable) on how the body absorbs, makes available, and removes zidovudine (ZDV). This study will also evaluate the differences in men and women in how the body absorbs, makes available, and removes ZDV. Past research has shown that the effectiveness of ZDV as an anti-HIV drug might be decreased in individuals who use certain methods of birth control. ZDV may also have different effects in men compared to women.
NCT00003179 ↗ Surgery Plus Medroxyprogesterone in Preventing Endometrial Cancer Terminated National Cancer Institute (NCI) Phase 2 1998-11-01 RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of surgery with or without medroxyprogesterone may be an effective way to prevent the development of endometrial cancer in patients who have endometrial hyperplasia. PURPOSE: Phase II trial to compare the effectiveness of surgery alone with that of medroxyprogesterone followed by surgery in preventing endometrial cancer in patients who have endometrial hyperplasia.
NCT00003179 ↗ Surgery Plus Medroxyprogesterone in Preventing Endometrial Cancer Terminated Gynecologic Oncology Group Phase 2 1998-11-01 RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of surgery with or without medroxyprogesterone may be an effective way to prevent the development of endometrial cancer in patients who have endometrial hyperplasia. PURPOSE: Phase II trial to compare the effectiveness of surgery alone with that of medroxyprogesterone followed by surgery in preventing endometrial cancer in patients who have endometrial hyperplasia.
NCT00016601 ↗ Depo-Medroxyprogesterone Acetate (DMPA, Depo-Provera) Use With Certain Anti-HIV Drugs in HIV-Infected Women Completed Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) N/A 2001-06-01 The purpose of this study is to look at the level of depo-medroxyprogesterone acetate (DMPA or Depo-Provera) in the blood to see if is affected by certain anti-HIV drugs (nelfinavir [NFV], efavirenz [EFV], indinavir [IDV] in combination with ritonavir [RTV], and nevirapine [NVP]). This study will also look at the levels of these anti-HIV drugs to see if they are affected by DMPA. DMPA is a hormonal birth control method that is given as an injection. It is not known if taking DMPA together with anti-HIV drugs changes the amount of DMPA and/or the amount of anti-HIV drugs in the blood. If higher levels of DMPA occur, side effects may increase. If lower levels of anti-HIV drugs occur, the drugs may become less effective against HIV. This study will look at the levels of anti-HIV drugs and DMPA in the blood when these medications are used together.
NCT00016601 ↗ Depo-Medroxyprogesterone Acetate (DMPA, Depo-Provera) Use With Certain Anti-HIV Drugs in HIV-Infected Women Completed National Institute of Allergy and Infectious Diseases (NIAID) N/A 2001-06-01 The purpose of this study is to look at the level of depo-medroxyprogesterone acetate (DMPA or Depo-Provera) in the blood to see if is affected by certain anti-HIV drugs (nelfinavir [NFV], efavirenz [EFV], indinavir [IDV] in combination with ritonavir [RTV], and nevirapine [NVP]). This study will also look at the levels of these anti-HIV drugs to see if they are affected by DMPA. DMPA is a hormonal birth control method that is given as an injection. It is not known if taking DMPA together with anti-HIV drugs changes the amount of DMPA and/or the amount of anti-HIV drugs in the blood. If higher levels of DMPA occur, side effects may increase. If lower levels of anti-HIV drugs occur, the drugs may become less effective against HIV. This study will look at the levels of anti-HIV drugs and DMPA in the blood when these medications are used together.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Depo-subq Provera 104

Condition Name

Condition Name for Depo-subq Provera 104
Intervention Trials
Contraception 11
HIV 3
Dysfunctional Uterine Bleeding 3
HIV Infections 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Depo-subq Provera 104
Intervention Trials
Hemorrhage 5
Metrorrhagia 4
Uterine Hemorrhage 4
HIV Infections 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Depo-subq Provera 104

Trials by Country

Trials by Country for Depo-subq Provera 104
Location Trials
United States 160
Dominican Republic 3
Puerto Rico 2
Zimbabwe 2
Norway 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Depo-subq Provera 104
Location Trials
California 13
Pennsylvania 11
Texas 8
North Carolina 7
New York 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Depo-subq Provera 104

Clinical Trial Phase

Clinical Trial Phase for Depo-subq Provera 104
Clinical Trial Phase Trials
Phase 4 12
Phase 3 6
Phase 2/Phase 3 2
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Depo-subq Provera 104
Clinical Trial Phase Trials
Completed 37
Terminated 8
Recruiting 6
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Depo-subq Provera 104

Sponsor Name

Sponsor Name for Depo-subq Provera 104
Sponsor Trials
FHI 360 5
National Institute of Allergy and Infectious Diseases (NIAID) 4
National Cancer Institute (NCI) 4
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Depo-subq Provera 104
Sponsor Trials
Other 67
NIH 12
Industry 12
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
Moodys
Colorcon
Dow
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.